In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer ...

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

T-DXd significantly improved IDFS and reduced the risk of invasive disease or death by 53% compared to T-DM1 in high-risk, HER2-positive breast cancer patients. The trial demonstrated superior ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ NSCLC patients in Beamion Lung-1, with 8% complete responses and 69% partial ...

Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...

Iranian-backed Houthi rebels have raided a U.N. facility in Yemen’s capital, Sanaa, according to a U.N. official. All staff ...